Inflammatory Bowel Diseases最新文献_第9页

InflammationHypoxia-Inducible Factor Signaling Compensates for Aryl Hydrocarbon Receptor in Maintaining Gut Barrier Integrity. 炎症缺氧诱导因子信号补偿芳烃受体维持肠道屏障完整性。

IF 4.3 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-08-25 DOI: 10.1093/ibd/izaf155

Min-Gyu Gwak, Mee-Sun Kim, Sujung Park, Seo-Hee Oh, Young-In Kim, Jung-Hyun Kim, Sun-Young Chang

{"title":"InflammationHypoxia-Inducible Factor Signaling Compensates for Aryl Hydrocarbon Receptor in Maintaining Gut Barrier Integrity.","authors":"Min-Gyu Gwak, Mee-Sun Kim, Sujung Park, Seo-Hee Oh, Young-In Kim, Jung-Hyun Kim, Sun-Young Chang","doi":"10.1093/ibd/izaf155","DOIUrl":"https://doi.org/10.1093/ibd/izaf155","url":null,"abstract":"Background: Inflammatory bowel disease remains an enigma in terms of its etiology, with breakdown of the intestinal barrier attributed to the elusive leaky gut syndrome. In this study, we investigated the role of interplay between hypoxia-inducible factor (HIF) and aryl hydrocarbon receptor (AhR) in maintaining intestinal barrier homeostasis.Methods: An enteroid system and AhR-deficient mouse models were used, with HIF stabilized by a prolyl hydroxylase inhibitor. Barrier function of enteroids was assessed by measuring size, budding number, Ki-67+ cell proliferation, and tight junction-related gene expression. In mice, gut barrier function was evaluated by histology, bacterial translocation, and barrier-related transcripts.Results: AhR-deficient enteroids derived from the small intestinal crypts of AhR-deficient mice showed increased cellular proliferation and budding and decreased expression of tight junction molecules that regulate barrier permeability. Moreover, AhR-deficient mice showed enhanced bacterial translocation from normal flora in the mesenteric lymph nodes and spleen and elevated serum endotoxin concentrations, indicating enhanced barrier permeability in vivo. Stabilizing HIFs through a prolyl hydroxylase inhibitor restored the expression of barrier molecules in AhR-deficient enteroids and decreased the translocation of enteric bacteria, suggesting the restoration of gut barrier function.Conclusions: Our findings suggested that high intestinal permeability due to AhR deficiency can be ameliorated by the stabilization of HIFs, indicating a compensatory role in barrier maintenance. This discovery holds promise for advancing therapeutic strategies for patients with gut permeability issues such as inflammatory bowel disease.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ScreeningLessons from Prediction and Prevention of Type 1 Diabetes. 预测和预防1型糖尿病的筛选经验教训。

IF 4.3 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-08-25 DOI: 10.1093/ibd/izaf175

Cate Speake, Adam Lacy-Hulbert, James Lord, Carla Greenbaum

{"title":"ScreeningLessons from Prediction and Prevention of Type 1 Diabetes.","authors":"Cate Speake, Adam Lacy-Hulbert, James Lord, Carla Greenbaum","doi":"10.1093/ibd/izaf175","DOIUrl":"https://doi.org/10.1093/ibd/izaf175","url":null,"abstract":"Two major accomplishments in the field of prediction and prevention have had important implications for type 1 diabetes (T1D), as well as other immune-mediated diseases such as inflammatory bowel disease (IBD). First, individuals destined to develop T1D can now be identified by testing for the presence of autoantibodies, long before signs or symptoms of clinical disease. Second, there is now an FDA-approved therapy to delay disease progression. These accomplishments were made possible by more than 4 decades of multicenter research, sustained commitments from funders, a culture of collaboration that enabled international standardization of autoantibody measurements, and common entry criteria and outcome measures for clinical trials. Robust data find that essentially everybody with 2 or more autoantibodies will eventually progress to clinical disease. This concept is now codified as stages of T1D, whereby those with multiple autoantibodies are considered to have early-stage disease. This provided a pathway for regulatory approval by clarifying that therapy was aimed at treating people with disease in contrast to preventing disease in healthy individuals and has helped antibody-positive individuals understand risk. Translating these scientific accomplishments into clinical practice remains challenging, but the availability of an approved therapy to delay T1D onset suggests that such translation is on the horizon for T1D and ultimately for other immune-mediated diseases.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: A Role for Leucine-Rich α2-Glycoprotein in Leukocyte Trafficking and Mucosal Inflammation in Inflammatory Bowel Disease. 更正：富亮氨酸α2糖蛋白在炎症性肠病中白细胞运输和粘膜炎症中的作用。

IF 4.3 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-08-25 DOI: 10.1093/ibd/izaf198

引用次数: 0

Revolutionizing IBD Clinical Trials with Bayesian Approaches. 用贝叶斯方法革新IBD临床试验。

IF 4.3 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-08-25 DOI: 10.1093/ibd/izaf182

Nurulamin M Noor, Haiyan Zheng, David S Robertson, Siddharth Singh

引用次数: 0

Comment on "Plasma Calprotectin and Myeloperoxidase as Biomarkers in Inflammatory Bowel Disease". 血浆钙保护蛋白和髓过氧化物酶作为炎症性肠病的生物标志物

IF 4.3 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-08-23 DOI: 10.1093/ibd/izaf192

Merve Eren Durmus, Gokhan Koker

引用次数: 0

Role of lncRNA MGP202 in Modulating B Cell Dynamics and Its Implications in Ulcerative Colitis. lncRNA MGP202在溃疡性结肠炎中调节B细胞动力学的作用及其意义。

IF 4.3 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-08-23 DOI: 10.1093/ibd/izaf176

Runing Zhou, Xiaoyin Bai, Dongdong Zhang, Yashu Zhu, Xuyang Dong, Meixu Wu, Mingyue Guo, Liu Yang, Hong Yang, Jiaming Qian

{"title":"Role of lncRNA MGP202 in Modulating B Cell Dynamics and Its Implications in Ulcerative Colitis.","authors":"Runing Zhou, Xiaoyin Bai, Dongdong Zhang, Yashu Zhu, Xuyang Dong, Meixu Wu, Mingyue Guo, Liu Yang, Hong Yang, Jiaming Qian","doi":"10.1093/ibd/izaf176","DOIUrl":"https://doi.org/10.1093/ibd/izaf176","url":null,"abstract":"Background: The upregulation of long noncoding RNA (lncRNA) MGP202 in ulcerative colitis (UC) patients suggests its potential significance in the disease. Understanding its role in UC pathogenesis and its impact on B cell dynamics is crucial for diagnostic and therapeutic advancements.Methods: We investigated the expression and function of MGP202 in UC patients by examining its localization in colon specimens, performing knockdown and overexpression experiments in Raji B cells, and evaluating its interaction with hsa-miR-5590-3p. Furthermore, we explored the downstream effect on interleukin-33 (IL-33) expression.Results: We found elevated expression of MGP202 in UC patients compared to healthy controls. Knockdown of MGP202 impeded B cell proliferation, while overexpression enhanced it. Direct binding between MGP202 and hsa-miR-5590-3p was confirmed. IL-33 expression decreased with hsa-miR-5590-3p overexpression but increased with MGP202 overexpression. Increased IL-33 levels were detected in the colon mucosa of UC patients.Conclusions: Our study reveals the upregulation of MGP202 in UC patients and its regulation of B cell proliferation through sponging hsa-miR-5590-3p and modulating IL-33 expression. These findings highlight MGP202 as a potential diagnostic and therapeutic target for UC, particularly in the context of B cell dynamics. Further investigations are warranted to evaluate clinical applicability and unravel additional mechanisms related to MGP202 modulation of B cell behavior in UC.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rewiring of Transcription Factor Binding: Another Piece of the Intricate Puzzle of IBD Pathogenesis. 转录因子结合的重新布线：IBD发病机制的另一个复杂谜团。

IF 4.3 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-08-23 DOI: 10.1093/ibd/izaf181

Claudio Fiocchi, Dimitrios Iliopoulos

引用次数: 0

InflammationBacterial Dysbiosis Observed in the Terminal Ileum of Ulcerative Colitis. 溃疡性结肠炎回肠末端细菌生态失调的观察。

IF 4.3 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-08-22 DOI: 10.1093/ibd/izaf160

Jordan S Mar, Allen Nguyen, Alexis Scherl, May Wittke, Mary Doona, Christopher A Lamb, Mary E Keir

引用次数: 0

Systematic Review With Meta-Analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Diseases. 系统评价与荟萃分析：生物制剂与小分子联合治疗炎症性肠病的安全性和有效性。

IF 4.3 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-08-22 DOI: 10.1093/ibd/izaf188

Scott R Anderson, Ali Osman, Mohammad Zamani, Quazim Alayo, Andres J Yarur, Deborah Thomas, Suzannah Bergstein, Elizabeth Spencer, Bruce E Sands, Jean-Francois Rahier, Jean-Frederic Colombel, Parakkal Deepak

{"title":"Systematic Review With Meta-Analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Diseases.","authors":"Scott R Anderson, Ali Osman, Mohammad Zamani, Quazim Alayo, Andres J Yarur, Deborah Thomas, Suzannah Bergstein, Elizabeth Spencer, Bruce E Sands, Jean-Francois Rahier, Jean-Frederic Colombel, Parakkal Deepak","doi":"10.1093/ibd/izaf188","DOIUrl":"https://doi.org/10.1093/ibd/izaf188","url":null,"abstract":"Background: The systematic review and meta-analysis (SRMA) evaluates the safety and effectiveness of combining biologics and/or small molecules in treating refractory inflammatory bowel diseases (IBD).Methods: Our 2022 SRMA identified 13 studies published until November 3, 2020. An updated systematic search was completed from May 2020 through January 31, 2024. Random-effects inverse variance model was used to calculate pooled estimates for adverse events (AEs) and clinical and endoscopic-radiologic response/remission rates in IBD patients.Results: Twenty-seven eligible studies had 619 patients and 631 therapeutic trials (TTs). Upadacitinib (UPA) + vedolizumab (VDZ) and tofacitinib (Tofa) + anti-TNF (aTNF) had the lowest AEs rate (0%, 2 TTs) and (9.2%, 33 TTs), respectively. Higher AE rates were seen in natalizumab (NAT) + aTNF (92.3%, 52 TTs) and aTNF + guselkumab (63.4%, 71 TTs). No serious AEs (SAEs) were observed in NAT + aTNF (52 TTs), Tofa + ustekinumab (UST) (23 TTs), and UPA + VDZ (2 TTs). The highest rate of SAEs was observed in UPA + UST (23%, 17 TTs). UPA + UST and UPA + VDZ had 100% clinical response rates and the highest clinical remission rates (83.3%, 12 TTs) and (100%, 2 TTs), respectively. High clinical response rates were also seen in Tofa + aTNF (82.7%, 34 TTs), UST + aTNF (82.1%, 63 TTs), and VDZ + UST (82.0%, 71 TTs).Conclusions: Combining biologics and/or small molecules may be effective for IBD patients who fail to achieve remission with monotherapy; however, safety profiles need to be carefully considered prior to implementing these strategies in clinical practice.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to Letter to the Editor Regarding "Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at One Year for Ulcerative Proctitis". 关于“溃疡性直肠炎一线先进疗法一年疗效、治疗持久性和安全性的真实世界比较”致编辑的回复。

IF 4.3 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-08-21 DOI: 10.1093/ibd/izaf157

Rahul S Dalal, Jessica R Allegretti

引用次数: 0